Novo Nordisk plans to invest more than €2.1 billion to expand manufacturing capacity at its site in Chartres, France to support its current and future product portfolio. The expansion will more than double the footprint of the site and entails adding aseptic and finished production processes and extending its Quality Control lab.
 
The expansion program will increase manufacturing capacity for its GLP-1 products, namely Ozempic and Wegovy, to meet increasing and future demand.
 
The company has initiated construction, which is expected to be finalized from 2026 to 2028. Once completed, the company expects to add more than 500 employees to run production activities.
 
“This significant investment confirms the importance of our French manufacturing site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company. By maximizing the skills and infrastructure we already have on the site, we are expanding our capacity in an efficient way,” said Lone Charlotte Larsen, corporate vice president of Novo Nordisk Production Chartres.